Clinical Experience

Clinical Experience

Protocol

MLP-001

Location

China

Clinical Phase

Phase I

Indication

Healthy Volunteers

Completed

Protocol

WEX-US-001

Location

Canada / US

Clinical Phase

Phase I

Indication

PK study in Healthy
Male Volunteers

Completed

Protocol

WEX-001

Location

Canada

Clinical Phase

Phase I

Indication

Healthy Volunteers

Completed

Protocol

WEX-002

Location

Canada

Clinical Phase

Phase I

Indication

Healthy Volunteers

Completed

Protocol

WEX-015

Location

Canada

Clinical Phase

Phase I

Indication

Healthy Volunteers

Completed

Protocol

MLP-002

Location

China

Clinical Phase

Phase IIa

Indication

Cancer Patients (Refractory Pain)

Completed

Protocol

WEX-003

Location

Canada

Clinical Phase

Phase IIa

Indication

Cancer Patients (Refractory Pain)

Completed

Protocol

WEX-008

Location

Canada

Clinical Phase

Phase IIa

Indication

Cancer Patients (Refractory Pain)

Completed

Protocol

WEX-014

Location

Canada

Clinical Phase

Phase IIb

Indication

Cancer Patients (Refractory Pain)

Completed

Protocol

WEX-014OL

Location

Canada

Clinical Phase

Phase IIb

Indication

Cancer Patients (Refractory Pain)

Completed

Protocol

TEC-006

Location

Canada/Australia/
New Zealand

Clinical Phase

Phase III

Indication

Cancer Patients (Refractory Pain)

Completed

Protocol

TEC-006OL

Location

Canada/Australia/New Zealand

Clinical Phase

Phase III

Indication

Cancer Patients (Refractory Pain)

Completed

Protocol

TTX-CINP-201-PK

Location

United States

Clinical Phase

Phase I

Indication

PK Study in Healthy Volunteers

Completed

Protocol

TTX-CINP-201

Location

United States

Clinical Phase

Phase II

Indication

Chemotherapy-Induced Neuropathic Pain

Completed

Protocol

TTX-TQT-101

Location

United States

Clinical Phase

Phase I

Indication

Cardiovascular Effect of Tetrodotoxin in Healthy Volunteers

Completed